BeNeLuxBelgiumNetherlandsLuxembourg

EMA tests procedure for early stage drugs

26.10.2010

Brussels - Healthcare institutions from Europe have launched a new pilot
process testing multi-stakeholder consultations in early-stage drug
development. The purpose of the project is to reach an agreement about what
constitutes a medicine’s value and the evidence required to demonstrate that
value most effectively, the European Medicines Agency said on its website.
The initiative is funded by the companies AstraZeneca, GlaxoSmithKline and
Johnson & Johnson.
The pilot initiative involves clinicians, health technology assessors
(HTAs), patient representatives, payers, regulators and drug developers from
France, Germany, Italy, the Netherlands, Sweden, the United Kingdom and
staff from the European Medicines Agency.
Participating companies will seek early advice regarding a medicine under
development for the treatment of either breast cancer or type 2 diabetes,
with consultations planned over the next four months. The agreed
consultation process will engage all participants on issues of therapeutic
value and a narrower group of HTAs and payers on questions of economic value deriving from therapeutic benefits.
Consultation recommendations will be non-binding and will not supercede
existing advice processes. Participants anticipate that this experimental
initiative could help shape subsequent pilots and broader initiatives for
early consultation. The pilots arose from the European Healthcare Innovation
Leadership Network. The Network comprises healthcare leaders from across
Europe who are committed to addressing the complementary goals of improving patient health outcomes and enhancing the climate for in

BeNeLuxBelgiumNetherlandsLuxembourg

29.03.2012

Brussels – Promethera Biosciences has completed a Series B financing round, generating proceeds of €23.6m. The Belgian cell therapy company secured a capital increase of €17m from its new investors, among them the venture arms...

BeNeLuxBelgiumNetherlandsLuxembourg

19.03.2012

Leuven – Biopharmaceutical company ThromboGenics has entered into an agreement with Alcon Inc., a division of Novartis for the commercialisation of its product ocriplasmin in all markets outside the U.S. ThromboGenics said it...

BeNeLuxBelgiumNetherlandsLuxembourg

07.03.2012

Amsterdam Molecular Therapeutics has announced a financial manoeuvre aimed at getting the biotech out of a hopeless situation. The assets and – more importantly – the liabilities of the drug developer will be acquired by a newly...

BeNeLuxBelgiumNetherlandsLuxembourg

20.02.2012

Amsterdam - Amsterdam Molecular Therapeutics has announced a financial manoeuvre which is aimed to get the biotech out of a dead end. The assets and – more importantly – the liabilities of the drug developer will be acquired by...

BeNeLuxBelgiumNetherlandsLuxembourg

10.02.2012

Glasgow/Leuven - With a little help from the EU, two biotech companies are banding together to develop the first stem cell therapy against rheumatoid arthritis. UK-based Sistemic will work with TiGenix to develop the Belgian's...

BeNeLuxBelgiumNetherlandsLuxembourg

25.01.2012

Amsterdam – Two elephants in the biofuels business join forces. Dutch food and chemicals group Royal DSM and POET, LLC, a US-based ethanol producer, announced a plan to build a commercial cellulosic ethanol plant. POET–DSM...

BeNeLuxBelgiumNetherlandsLuxembourg

13.01.2012

Heerlen - Royal DSM N.V will be the industrial partner to the Panoptes consortium, which aims to develop novel drug delivery technology for the posterior eye segment. The four year project is supported by EUR4m in funding from...

BeNeLuxBelgiumNetherlandsLuxembourg

04.01.2012

Leiden - Dutch Pharming Group NV has taken a further step to secure sound financing even beyond the recent milestone payments. The drug developer announced that it has entered into a financing of approximately €8.4 million by...

BeNeLuxBelgiumNetherlandsLuxembourg

16.12.2011

Ghent – Just days after US pharmaceuticals giant Pfizer pulled out of a rheumatoid arthritis pact with Ablynx NV, the Belgian biopharmaceutical company expanded its relationship with Merck Serono. Ablynx has now entered into a...

Displaying results 1 to 10 out of 304

1-10 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/news/messages-archive/archive-benelux/article/ema-tests-procedure-for-early-stage-drugs.html

Product of the week

Products

Events

All Events

Current issue

All issues